Stock Region Watchlist
Top 3 Stocks to Watch Now
Top 3 Stocks to Watch Now
The stocks featured in this report were previously delivered in our trading room in real-time. To access Stock Region’s real-time trade ideas, then be sure to purchase a membership now.
Disclaimer: This is not financial advice. The content in this newsletter is for informational and entertainment purposes only. You should not construe any such information as legal, tax, investment, financial, or other advice. Please do your own research and consult with a licensed financial professional before making any investment decisions.
What a week it’s been. The market keeps throwing curveballs, yet fresh opportunities always emerge. After digging through the noise, it’s time to highlight three companies making serious moves—definitely worth a closer look. Let’s jump in.
PNC Financial Services Group ($PNC) - The Quiet Giant Wakes Up
PNC often gets labeled one of the steady, “boring” big banks, but take a look at the latest earnings report. The company absolutely crushed it with a 25% jump in fourth-quarter profits—a massive feat for such a large enterprise.
The real highlight? A 41% surge in capital markets revenue, showing the bank is firing on all cylinders, especially with M&A activity heating up. Rather than sitting back and collecting interest, PNC is actively making deals and growing. Add in a major Western acquisition and plans for a substantial share buyback, and it’s clear management feels confident. When management puts money behind their message, it’s a big vote of confidence.
Opinion: Banks have been hit-or-miss lately, but PNC is showing some impressive strength. That record $6.07 billion revenue speaks volumes.
Levels to watch: Upside above $225.06 could mean a breakout. Drop below $221.00 may signal short-term weakness.
ImmunityBio ($IBRX) - A Biotech with Heart
Biotech stories rarely offer both massive potential and genuine positive impact, but IBRX delivers on both fronts. The stock has already doubled this year, thanks to the outstanding results from the ANKTIVA bladder cancer treatment trials—an 85% complete response rate is truly remarkable compared to the current standard.
Beyond the science, ImmunityBio is addressing the BCG shortage, ensuring patients continue to have vital treatments available. This builds real goodwill within the healthcare community. With a BLA submission to the FDA expected by year’s end, big developments could be ahead. Stories like this, where innovation improves lives, always inspire excitement.
Opinion: High risk, high reward is the name of the game for biotech, but the numbers here are compelling. The company has real momentum and a clear sense of purpose.
Levels to watch: Above $4.95 could trigger another rally. Below $4.31, a new support level may need to form.
Coupang ($CPNG) - The King of Korean E-Commerce
While attention often centers on US tech giants, Coupang is quietly building a retail empire in South Korea. Imagine Amazon, but with even greater obsession over logistics and speed. Growth has been impressively consistent, with market share on a steady climb.
Coupang understands profitability in a notoriously tough sector, delivering efficiency few can match. As expansion into new markets continues, the blueprint for success is clear. This isn’t a flashy meme stock; think of Coupang as a powerhouse with a bright, long-term future that’s only getting started.
Opinion: E-commerce is here to stay, and Coupang stands out as a best-in-class operator. It’s easy to be optimistic about this strategy for long-term growth.
Levels to watch: A push over $22.05 looks bullish. A dip below $21.87 could present a buying opportunity, so keep an eye on support.
That wraps it up for today. Keep these tickers on the radar and trade thoughtfully.
Best,
The Stock Region Team
Disclaimer: All trading and investment decisions are your own responsibility. The information provided by Stock Region is not a recommendation to buy or sell any security. We may or may not hold positions in the stocks mentioned. Past performance is not indicative of future results.
Appreciate the focus on CPNG's operational model rather than just hyping the growth story. The logistics obsession angle is what actually seperates them from other e-commerce plays, especially in a dense market like Korea where delivery speed can be a real moat. Most retail investors overlook how hard it is to build that kind of infrastructure advantage. The comparison to Amazon makes sense but I'd argue CPNG's execution on last-mile has been even tighter given the urban density they're working with. Been watching their profitablity trajectory and it seems like they've figured out unit economics way faster than most. The key question is if they can replicate this playbook in other Asian markets without burning through cash.